Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone

1. T. Cabaleiro, D. Ochoa, R. López-Rodríguez, M. Román, J. Novalbos, C. Ayuso and F. Abad-Santos, Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers, Hum. Psychopharmacol. 29 (2014) 459-469; DOI: 10.1002/hup.2420.10.1002/hup.242025042870Search in Google Scholar

2. J. L. Sun, Q. X. Chen, S. Tian, F. R. Meng, Y. Lv and G. H. Du, Absorption of risperidone polymorphs administrated orally in rats, Chin. Pharm. J. 46 (2011) 1919-1922.Search in Google Scholar

3. T. K. Vyas, A. Shahiwala, S. Marathe and A. Misra, Intranasal drug delivery for brain targeting, Curr. Drug Deliv. 2 (2005) 165-175; DOI: 10.2174/1567201053586047.10.2174/156720105358604716305417Search in Google Scholar

4. C. R. Behl, H. K. Pimplaskar, A. P. Sileno, J. deMeireles and V. D. Romeo, Effects of physicochemical properties and other factors on systemic nasal drug delivery, Adv. Drug Deliv. Rev. 29 (1998) 89-116; DOI: doi:10.1016/S0169-409X(97)00063-X.Search in Google Scholar

5. M. Kumar, A. Misra, A. K. Babbar, A. K. Mishra, P. Mishra and K. Pathak, Intranasal nanoemulsion based brain targeting drug delivery system of risperidone, Int. J. Pharm. 358 (2008) 285-291; DOI: 10.1016/j.ijpharm.2008.03.029.10.1016/j.ijpharm.2008.03.02918455333Search in Google Scholar

6. W. N. Ma and F. G. Gu, Effect of pH on the chemical stability, solubility and oil-water partition coefficient of risperidone, Centr. South Pharm. 13 (2015) 473-476; DOI: 10.7539/j.issn.1672-2981.2015.05.006.Search in Google Scholar

7. H. S. Mahajan, S. K. Shah and S. J. Surana, Nasal in situ gel containing hydroxy propyl β-cyclodextrin inclusion complex of arthemeter: development and in vitro evaluation, J. Incl. Phenom. Macrocycl. Chem. 70 (2011) 49-58; DOI: 10.1007/s10847-010-9861-x.10.1007/s10847-010-9861-xSearch in Google Scholar

8. C. Tas, C. K. Ozkan, A. Savaser, Y. Ozkan, U. Tasdemir and H. Altunay, Nasal absorption of metoclopramide from different Carbopol 981 based formulations: In vitro, ex vivo and in vivo evaluation, Eur. J. Pharm. Biopharm. 64 (2006) 246-254; DOI: 10.1016/j.ejpb.2006.05.017.10.1016/j.ejpb.2006.05.01716870409Search in Google Scholar

9. F. G. Gu, F. D. Cui and Y. L. Gao, Preparation of prostaglandin E1-hydroxypropyl-β-cyclodextrin complex and its nasal delivery in rats, Int. J. Pharm. 290 (2005) 101-108; DOI: 10.1016/j. ijpharm.2004.11.021.Search in Google Scholar

10. X. G. Jiang, J. B. Cui, X. L. Fang, Y. Wei and N. Z. Xi, Toxicity of drugs on nasal mucocilia and the method of its evaluation, Acta. Pharm. Sin. 30 (1995) 848-853; DOI: 10.3321/j.issn:0513-4870.1995.11.009.Search in Google Scholar

11. M. Jug, I. Kos and M. Bećirević-Laćan, The pH-dependent complexation between risperidone and hydroxypropyl-β-cyclodextrin, J. Incl. Phenom. Macrocycl. Chem. 64 (2009) 163-171; DOI: 10.1007/ s10847-009-9549-2.10.1007/s10847-009-9549-2Search in Google Scholar

12. T. Yang, A. Hussain, J. Paulson, T. J. Abbruscato and F. Ahsan, Cyclodextrinsin nasal delivery of low molecular weight heparins: in vivo and in vitro studies, Pharm. Res. 21 (2004) 1127-1136; DOI: 10.1023/B:PHAM.0000032998.84488.7a.10.1023/B:PHAM.0000032998.84488.7aSearch in Google Scholar

13. E. Marttin, J. C. Vethoef and F. W. H. M. Merkus, Efficacy safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs, J. Drug Targeting 6 (1998) 17-36; DOI: 10.3109/10611869808997878.10.3109/106118698089978789769018Search in Google Scholar

14. G. Rathnam, N. Narayanan and R. Ilavarasan, Carbopol-based gels for nasal delivery of progesterone, AAPS Pharm. Sci. Tech. 9 (2008) 1078-1082; DOI: 10.1208/s12249-008-9144-7.10.1208/s12249-008-9144-7262826518850277Search in Google Scholar

15. F. G.. Gu, D. Hao, G. D. L. Meng, C. Z. Wu and Y. Wang, Preparation of bisoprolol fumarate nasal spray and its nasal delivery in rats, Pak. J. Pharm. Sci. 28 (2015) 2173-2178.Search in Google Scholar